Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
Malar J. 2024 Feb 2;23(1):38. doi: 10.1186/s12936-024-04864-8.
It was hypothesized that glucose-6-phosphate dehydrogenase (G6PD) deficiency confers a protective effect against malaria infection, however, safety concerns have been raised regarding haemolytic toxicity caused by radical cure with 8-aminoquinolines in G6PD-deficient individuals. Malaria elimination and control are also complicated by the high prevalence of G6PD deficiency in malaria-endemic areas. Hence, accurate identification of G6PD deficiency is required to identify those who are eligible for malaria treatment using 8-aminoquinolines.
The prevalence of G6PD deficiency among 408 Thai participants diagnosed with malaria by microscopy (71), and malaria-negative controls (337), was assessed using a phenotypic test based on water-soluble tetrazolium salts. High-resolution melting (HRM) curve analysis was developed from a previous study to enable the detection of 15 common missense, synonymous and intronic G6PD mutations in Asian populations. The identified mutations were subjected to biochemical and structural characterisation to understand the molecular mechanisms underlying enzyme deficiency.
Based on phenotypic testing, the prevalence of G6PD deficiency (< 30% activity) was 6.13% (25/408) and intermediate deficiency (30-70% activity) was found in 15.20% (62/408) of participants. Several G6PD genotypes with newly discovered double missense variants were identified by HRM assays, including G6PD Gaohe + Viangchan, G6PD Valladolid + Viangchan and G6PD Canton + Viangchan. A significantly high frequency of synonymous (c.1311C>T) and intronic (c.1365-13T>C and c.486-34delT) mutations was detected with intermediate to normal enzyme activity. The double missense mutations were less catalytically active than their corresponding single missense mutations, resulting in severe enzyme deficiency. While the mutations had a minor effect on binding affinity, structural instability was a key contributor to the enzyme deficiency observed in G6PD-deficient individuals.
With varying degrees of enzyme deficiency, G6PD genotyping can be used as a complement to phenotypic screening to identify those who are eligible for 8-aminoquinolines. The information gained from this study could be useful for management and treatment of malaria, as well as for the prevention of unanticipated reactions to certain medications and foods in the studied population.
有人假设葡萄糖-6-磷酸脱氢酶(G6PD)缺乏对疟疾感染有保护作用,但 8-氨基喹啉类药物根治治疗引起的溶血性毒性引起了安全方面的担忧,而在疟疾流行地区,G6PD 缺乏症的高患病率也使疟疾的消除和控制变得复杂。因此,需要准确识别 G6PD 缺乏症,以确定那些有资格使用 8-氨基喹啉类药物治疗疟疾的人。
通过基于水溶性四唑盐的表型试验,评估了 408 名通过显微镜诊断为疟疾(71 名)和疟疾阴性对照(337 名)的泰国参与者中 G6PD 缺乏症的患病率。高分辨率熔解(HRM)曲线分析是从以前的研究中开发出来的,以检测亚洲人群中 15 种常见的错义、同义和内含子 G6PD 突变。对鉴定出的突变进行生化和结构特征分析,以了解酶缺乏的分子机制。
根据表型检测,G6PD 缺乏症(<30%活性)的患病率为 6.13%(25/408),中间缺乏症(30-70%活性)的患病率为 15.20%(62/408)。通过 HRM 检测发现了几种新发现的双重错义变异的 G6PD 基因型,包括 G6PD Gaohe+Viangchan、G6PD Valladolid+Viangchan 和 G6PD Canton+Viangchan。检测到具有中间至正常酶活性的同义(c.1311C>T)和内含子(c.1365-13T>C 和 c.486-34delT)突变的频率显著升高。双重错义突变的催化活性低于相应的单一错义突变,导致严重的酶缺乏。虽然这些突变对结合亲和力的影响较小,但结构不稳定性是导致 G6PD 缺乏个体中观察到的酶缺乏的关键因素。
G6PD 基因分型可作为表型筛选的补充,用于识别有资格使用 8-氨基喹啉类药物的患者,不同程度的酶缺乏。从这项研究中获得的信息可用于疟疾的管理和治疗,以及研究人群中某些药物和食物的意外反应的预防。